Telix Pharmaceuticals (NASDAQ:TLX) Rating Increased to Moderate Buy at Royal Bank Of Canada

Telix Pharmaceuticals (NASDAQ:TLX) was upgraded by research analysts at Royal Bank Of Canada from a “hold” rating to a “moderate buy” rating in a research report issued to clients and investors on Monday, Zacks reports.

Other research analysts also recently issued reports about the company. Citigroup reaffirmed a “buy” rating on shares of Telix Pharmaceuticals in a report on Thursday, August 20th. Wedbush restated an “outperform” rating and set a $22.00 target price on shares of Telix Pharmaceuticals in a research note on Monday, September 14th. HC Wainwright reaffirmed a “buy” rating and set a $20.00 price target on shares of Telix Pharmaceuticals in a report on Tuesday, September 15th. Finally, Weiss Ratings raised shares of Telix Pharmaceuticals from a “sell (d)” rating to a “hold (c-)” rating in a report on Friday, August 21st. One equities research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has given a Hold rating to the company. According to data from MarketBeat, the company presently has an average rating of “Buy” and a consensus target price of $20.40.

Telix Pharmaceuticals Price Performance

TLX stock opened at $11.31 on Monday. Telix Pharmaceuticals has a 12-month low of $6.28 and a 12-month high of $13.11. The company has a quick ratio of 1.85, a current ratio of 2.01 and a debt-to-equity ratio of 1.16. The stock’s 50 day simple moving average is $11.30 and its 200 day simple moving average is $10.38.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the stock. Hennion & Walsh Asset Management Inc. bought a new stake in Telix Pharmaceuticals during the 2nd quarter valued at approximately $1,731,000. Private Advisor Group LLC raised its position in shares of Telix Pharmaceuticals by 276.3% during the first quarter. Private Advisor Group LLC now owns 174,415 shares of the company’s stock valued at $1,669,000 after buying an additional 128,070 shares during the last quarter. XY Capital Ltd lifted its holdings in shares of Telix Pharmaceuticals by 468.0% in the second quarter. XY Capital Ltd now owns 71,291 shares of the company’s stock worth $822,000 after buying an additional 58,739 shares in the last quarter. Lazard Asset Management LLC lifted its holdings in shares of Telix Pharmaceuticals by 15.7% in the first quarter. Lazard Asset Management LLC now owns 289,917 shares of the company’s stock worth $2,775,000 after buying an additional 39,400 shares in the last quarter. Finally, Bank of America Corp DE grew its stake in Telix Pharmaceuticals by 523.8% during the first quarter. Bank of America Corp DE now owns 10,031 shares of the company’s stock valued at $96,000 after acquiring an additional 8,423 shares in the last quarter.

Telix Pharmaceuticals News Roundup

Here are the key news stories impacting Telix Pharmaceuticals this week:

• Positive Sentiment: Telix and ITM plan to combine their complementary businesses to create a larger radiopharmaceutical company, strengthening Telix’s access to radioisotope production, development capabilities and international markets. Telix and ITM Join Forces to Create a Radiopharmaceutical Powerhouse
• Positive Sentiment: The deal is intended to improve the security and scale of Telix’s isotope supply, potentially supporting future product launches, manufacturing growth and long-term revenue expansion. Telix and ITM merge to create a radiopharmaceutical powerhouse
• Positive Sentiment: Management’s merger presentation and call emphasized the strategic rationale for building a scaled radiopharmaceutical leader, which could create synergies and broaden Telix’s competitive position if integration is successful. Telix Pharmaceuticals M&A Call Transcript

Telix Pharmaceuticals Company Profile

Telix Pharmaceuticals Limited is a biopharmaceutical company focused on developing and commercializing radiopharmaceuticals for the diagnosis and treatment of cancer and other serious diseases. Its products use targeted molecules to deliver radioactive isotopes to specific tissues, supporting precision imaging and therapeutic applications.

The company’s commercial portfolio includes Illuccix, a gallium-68 radiolabeled prostate-specific membrane antigen (PSMA) imaging agent used with PET scans to help detect and manage prostate cancer.